Thelansis

 Epstein–Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) of both younger and elderly population and was defined as EBV-positive monoclonal large B-cell proliferative disease. The survival of patients with EBV-positive DLBCL is significantly worse than that of patients with EBV-negative DLBCL. Cells with latent EBV infection express EBER protein and may express other proteins such as EBNA and LMP proteins. EBV also induces the NFκB pathway, which may be required for the survival of the cells in DLBCL. The immunohistochemical profile is generally positive for B-cell markers CD20, CD19, CD79a, and PAX-5. CD10 and BCL6 are usually negative, while MUM1 is commonly positive. Cases with immunoblastic or plasmablastic features may lack CD20 expression. In situ hybridization for EBER is positive and is considered the most important test in diagnosis, with the highest diagnostic sensitivity. EBV+ DLBCL has a poor response to treatment, so rapid detection is a necessity. · ...

 Epstein–Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) of both younger and elderly population and was defined as EBV-positive monoclonal large B-cell proliferative disease. The survival of patients with EBV-positive DLBCL is significantly worse than that of patients with EBV-negative DLBCL. Cells with latent EBV infection express EBER protein and may express other proteins such as EBNA and LMP proteins. EBV also induces the NFκB pathway, which may be required for the survival of the cells in DLBCL. The immunohistochemical profile is generally positive for B-cell markers CD20, CD19, CD79a, and PAX-5. CD10 and BCL6 are usually negative, while MUM1 is commonly positive. Cases with immunoblastic or plasmablastic features may lack CD20 expression. In situ hybridization for EBER is positive and is considered the most important test in diagnosis, with the highest diagnostic sensitivity. EBV+ DLBCL has a poor response to treatment, so rapid detection is a necessity. · ...